Collegium Pharmaceutical, Inc.

NasdaqGS:COLL Aktierapport

Börsvärde: US$1.1b

Collegium Pharmaceutical Förvaltning

Förvaltning kriterier kontrolleras 4/4

Collegium Pharmaceutical VD är Vikram Karnani, utsedd i Nov 2024, har en mandatperiod på 1.5 år. totala årliga ersättningen är $ 1.72M, bestående av 51% lön 49% bonusar, inklusive företagsaktier och optioner. äger direkt 0.12% av företagets aktier, värda $ 1.32M. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 2.8 år respektive 10.6 år.

Viktig information

Vikram Karnani

Verkställande direktör

US$1.7m

Total ersättning

VD-lön i procent51.00%
Anställning som VD1.5yrs
Ägande av VD0.1%
Ledningens genomsnittliga anställningstid2.8yrs
Styrelsens genomsnittliga mandatperiod10.6yrs

Senaste uppdateringar av ledningen

Recent updates

COLL: Affordable Medicines Theme Will Support 2026 Earnings Conviction And Upside Potential

Analysts have raised their price target on Collegium Pharmaceutical by $3, citing updated assumptions about revenue growth, profit margin expectations, and a slightly revised P/E multiple as the main factors behind the change. Analyst Commentary Bullish Takeaways Bullish analysts view the $3 price target increase as support for their view that updated revenue assumptions still justify a premium to prior expectations.

COLL: Affordable Medicines Theme Will Support 2026 Earnings Strength And Risk Reward Upside

Analysts have raised their price target on Collegium Pharmaceutical by $3 to reflect updated assumptions around valuation inputs, while keeping fair value, discount rate, revenue growth, profit margin, and future P/E estimates essentially unchanged. Analyst Commentary Bullish Takeaways Bullish analysts view the $3 price target increase as confirmation that their core valuation framework on fair value, discount rate, and P/E assumptions still holds, which can signal confidence in the company’s ability to execute on its current plan.

COLL: Affordable Medicines Theme Will Support 2026 Margin Resilience And Earnings Strength

Analysts have slightly increased their consolidated price target for Collegium Pharmaceutical by about $0.33 per share, citing updated assumptions for modest revenue growth, higher profit margins, and a lower future P/E multiple that reflect recent Street research from Truist and Barclays. Analyst Commentary Recent research updates on Collegium Pharmaceutical show a mix of optimism and caution as analysts refresh their models around the company’s 2026 outlook, valuation framework, and earnings power.

Collegium Pharmaceutical: Another M&A Episode Adds To An Intriguing Case

Mar 20

COLL: Affordable Medicines Theme Will Support 2026 Margin Expansion And Higher Earnings Power

Narrative Update on Collegium Pharmaceutical The analyst price target for Collegium Pharmaceutical has edged up by about $0.17, supported by recent Street research that combines slightly softer revenue growth assumptions with higher expected profit margins and a modestly lower future P/E multiple. Analyst Commentary Recent Street research on Collegium Pharmaceutical reflects a mix of optimism and caution around the updated price targets and longer term outlook, with views centering on how well the company can execute against its 2026 framework and how that is captured in current valuation multiples.

COLL: Affordable Medicines Theme Will Support 2026 Earnings Visibility And Upside P/E Rerating

Analysts raised their fair value estimate for Collegium Pharmaceutical by about $0.50 per share to $53.67, reflecting recent shifts in Street price targets and updated views on long term revenue trends, margins, and the appropriate future P/E multiple. Analyst Commentary Recent Street research on Collegium Pharmaceutical shows a mix of optimism and caution around the updated price targets and earnings outlook into 2026.

COLL: Affordable Medicines Focus Will Support Constructive 2026 Outlook Upside

Narrative Update on Collegium Pharmaceutical Analysts have kept their fair value estimate for Collegium Pharmaceutical steady at about $53.17 per share, with modest model tweaks around discount rate and future P/E, reflecting recent price target adjustments to $55 and $56 tied to updated 2026 outlooks and an ongoing focus on affordable medicines. Analyst Commentary Recent research updates point to a fairly constructive stance on Collegium Pharmaceutical, with price targets clustered in the mid US$50s and models now aligned with the initial 2026 outlook and an emphasis on affordable medicines.

COLL: 2026 Outlook And Affordable Medicines Theme Will Support Upside Potential

Analysts have trimmed their average price target for Collegium Pharmaceutical to about $55, with adjustments clustered around US$55 to US$56 as they update models for the company's initial 2026 outlook and lean into the affordable medicines theme. Analyst Commentary Bullish Takeaways Bullish analysts see the updated fiscal 2026 outlook as solid enough to support price targets around US$55 to US$56, which they view as aligned with their current models.

COLL: 2026 Earnings Outlook And Affordable Medicines Theme Will Drive Returns

Analysts have raised their fair value estimate for Collegium Pharmaceutical to about $53.17 from $48.67, citing updated price targets around $55 to $56 and revised views on 2026 earnings potential and profitability. Analyst Commentary Recent research on Collegium Pharmaceutical is centered on updated price targets and how the initial 2026 outlook feeds into views on earnings power and profitability.

COLL: Higher 2025 Revenue Guidance And Stable Outlook Will Shape Future Returns

Analysts have modestly raised their price target on Collegium Pharmaceutical from approximately $47 to $48.67 per share. This reflects slightly improved fair value estimates supported by stable discount rate assumptions, largely unchanged long term revenue and margin expectations, and a somewhat higher anticipated future earnings multiple.

COLL: Steady Outlook And Higher 2025 Revenue Guidance Will Shape Future Returns

Analysts have reiterated their price target for Collegium Pharmaceutical at approximately 46.80 dollars, citing largely unchanged assumptions for the discount rate, revenue trajectory, profit margins, and future valuation multiples that support a stable fair value outlook. What's in the News Collegium Pharmaceutical raised its full year 2025 net product revenue guidance to a range of 775 million to 785 million dollars, up from the prior 745 million to 760 million dollar outlook (company guidance).

COLL: Increased Revenue Guidance And Margin Shifts Will Shape Measured Future Returns

Collegium Pharmaceutical’s analyst price target remains unchanged at $46.80, as analysts point to a balanced outlook where revisions to profit margin and future P/E estimates offset each other. What's in the News Collegium Pharmaceutical raised its 2025 net product revenue guidance and now expects a range of $775 to $785 million, up from the previous range of $745 million to $760 million (Key Developments).

Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) 28% Jump Shows Its Popularity With Investors

Nov 08
Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) 28% Jump Shows Its Popularity With Investors

COLL: Higher Margins And Full-Year Guidance Will Support Balanced Future Returns

Analysts have raised their price target for Collegium Pharmaceutical from $44.60 to $46.80. This reflects improved expectations for profit margins even though projected revenue growth is lower.

We Think Collegium Pharmaceutical (NASDAQ:COLL) Is Taking Some Risk With Its Debt

Oct 19
We Think Collegium Pharmaceutical (NASDAQ:COLL) Is Taking Some Risk With Its Debt

Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) P/E Still Appears To Be Reasonable

Jul 31
Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) P/E Still Appears To Be Reasonable

There May Be Reason For Hope In Collegium Pharmaceutical's (NASDAQ:COLL) Disappointing Earnings

May 16
There May Be Reason For Hope In Collegium Pharmaceutical's (NASDAQ:COLL) Disappointing Earnings

Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Has Caught The Eye Of Investors

Apr 07
Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Has Caught The Eye Of Investors

Collegium Pharmaceutical: Checking The Boxes

Mar 03

Improved Revenues Required Before Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Find Their Feet

Dec 24
Improved Revenues Required Before Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Find Their Feet

Collegium Pharmaceutical: Strong Growth With Pain Management And ADHD Expansion

Nov 26

Shareholders Can Be Confident That Collegium Pharmaceutical's (NASDAQ:COLL) Earnings Are High Quality

Nov 14
Shareholders Can Be Confident That Collegium Pharmaceutical's (NASDAQ:COLL) Earnings Are High Quality

Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?

Oct 28
Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?
User avatar

Ironshore Acquisition And Calculated Moves Set To Propel Growth In ADHD Market

Collegium Pharmaceutical's acquisition of Ironshore Therapeutics positions them in the ADHD market, aiming for revenue growth through diversified offerings and operational efficiencies.

Collegium Pharmaceutical: Diversifying And Growing

Aug 09

Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Right But Growth Is Lacking

Jul 24
Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Right But Growth Is Lacking

Collegium Pharmaceutical (NASDAQ:COLL) Seems To Use Debt Quite Sensibly

Jun 05
Collegium Pharmaceutical (NASDAQ:COLL) Seems To Use Debt Quite Sensibly

Collegium Pharmaceutical: Some Positives From Its Quarterly 'Miss'

May 13

It Looks Like Shareholders Would Probably Approve Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Package

May 10
It Looks Like Shareholders Would Probably Approve Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Package

Analys av ersättningar till VD

Hur har Vikram Karnani:s ersättning förändrats jämfört med Collegium Pharmaceutical:s resultat?
DatumTotal ersättningLönFöretagets resultat
Dec 31 2025US$2mUS$875k

US$63m

Sep 30 2025n/an/a

US$58m

Jun 30 2025n/an/a

US$36m

Mar 31 2025n/an/a

US$44m

Dec 31 2024US$11mUS$98k

US$69m

Ersättning vs marknad: Vikram s total kompensation ($USD 1.72M ) är under genomsnittet för företag av liknande storlek på US marknaden ($USD 3.69M ).

Ersättning vs inkomst: Ersättningen från Vikram har varit i linje med företagets resultat under det senaste året.

VD OCH KONCERNCHEF

Vikram Karnani (50 yo)

1.5yrs
Anställning
US$1,715,846
Kompensation

Mr. Vikram Karnani is Independent Director of Dyne Therapeutics, Inc. from December 22, 2025. Mr. Karnani is CEO, President & Director of Collegium Pharmaceutical, Inc. since November 12, 2024 and served a...

Ledningsgrupp

NamnPositionAnställningKompensationÄgarskap
Vikram Karnani
CEO, President & Director1.5yrsUS$1.72m0.12%
$ 1.3m
Colleen Tupper
Executive VP & CFO5yrsUS$3.52m0.19%
$ 2.1m
David Dieter
Executive VP1.2yrsUS$3.97m0.0013%
$ 13.7k
Scott Dreyer
Executive VP & Chief Commercial Officer7.8yrsUS$3.04m0%
$ 0
Thomas Smith
Executive VP & Chief Medical Officer4.2yrsUS$2.45m0.11%
$ 1.2m
Ian Karp
Head of Investor Relationsno datainga uppgifteringa uppgifter
Jessica Cotrone
Senior Vice President of Communications & Corporate Affairsno datainga uppgifteringa uppgifter
Jane Gonnerman
Executive Vice President of Strategy & Corporate Development1.2yrsinga uppgifteringa uppgifter
Dean Patras
Chief People Officer1.2yrsinga uppgifteringa uppgifter
Scott Sudduth
EVP & Head of Technical Operations4.6yrsinga uppgifteringa uppgifter
2.8yrs
Genomsnittlig anställningstid
53yo
Genomsnittlig ålder

Erfaren ledning: COLL s ledningsgrupp anses vara erfaren ( 2.8 års genomsnittlig anställningstid).

Styrelseledamöter

NamnPositionAnställningKompensationÄgarskap
Vikram Karnani
CEO, President & Director1.5yrsUS$1.72m0.12%
$ 1.3m
John Freund
Independent Director12.3yrsUS$367.27k0.13%
$ 1.4m
Nancy Lurker
Independent Director1.3yrsUS$743.78k0.039%
$ 429.3k
Garen Bohlin
Independent Director11.3yrsUS$366.64k0.0069%
$ 76.0k
Gino Santini
Independent Chairman13.8yrsUS$400.96k0.11%
$ 1.2m
Bill McCarberg
Scientific Advisorno datainga uppgifteringa uppgifter
Robert Dworkin
Scientific Advisorno datainga uppgifteringa uppgifter
Lynn Webster
Scientific Advisorno datainga uppgifteringa uppgifter
John Fallon
Independent Director9.9yrsUS$366.27k0.17%
$ 1.8m
Cynthia McCormick
Scientific Advisorno datainga uppgifteringa uppgifter
Richard Rauck
Scientific Advisorno datainga uppgifteringa uppgifter
Charles Argoff
Scientific Advisorno datainga uppgifteringa uppgifter
10.6yrs
Genomsnittlig anställningstid
70yo
Genomsnittlig ålder

Erfaren styrelse: COLL s styrelse är rutinerade och erfaren ( 10.6 års genomsnittlig mandatperiod).

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/05/01 20:07
Aktiekurs vid dagens slut2026/05/01 00:00
Intäkter2025/12/31
Årlig intjäning2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Collegium Pharmaceutical, Inc. bevakas av 13 analytiker. 5 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Jenna DavidnerBarclays
Kenneth TrbovichBrean Capital Historical (Janney Montgomery)
Dana FlandersGuggenheim Securities, LLC